Correlation Between Molecular Partners and Structure Therapeutics
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Structure Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Structure Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and Structure Therapeutics American, you can compare the effects of market volatilities on Molecular Partners and Structure Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Structure Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Structure Therapeutics.
Diversification Opportunities for Molecular Partners and Structure Therapeutics
-0.22 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Molecular and Structure is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Structure Therapeutics America in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Structure Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Structure Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Structure Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Structure Therapeutics go up and down completely randomly.
Pair Corralation between Molecular Partners and Structure Therapeutics
Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.15 times more return on investment than Structure Therapeutics. However, Molecular Partners is 1.15 times more volatile than Structure Therapeutics American. It trades about 0.05 of its potential returns per unit of risk. Structure Therapeutics American is currently generating about 0.0 per unit of risk. If you would invest 420.00 in Molecular Partners AG on August 26, 2024 and sell it today you would earn a total of 109.00 from holding Molecular Partners AG or generate 25.95% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Molecular Partners AG vs. Structure Therapeutics America
Performance |
| Timeline |
| Molecular Partners |
| Structure Therapeutics |
Molecular Partners and Structure Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and Structure Therapeutics
The main advantage of trading using opposite Molecular Partners and Structure Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Structure Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will offset losses from the drop in Structure Therapeutics' long position.| Molecular Partners vs. Eliem Therapeutics | Molecular Partners vs. HCW Biologics | Molecular Partners vs. Scpharmaceuticals | Molecular Partners vs. Milestone Pharmaceuticals |
| Structure Therapeutics vs. Day One Biopharmaceuticals | Structure Therapeutics vs. X4 Pharmaceuticals | Structure Therapeutics vs. Inozyme Pharma | Structure Therapeutics vs. Acumen Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |